Navigation Links
ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
Date:1/7/2009

FREDERICK, Md., Jan. 7 /PRNewswire/ -- ImQuest Life Sciences announced today the successful submission of an IND application to the Food and Drug Administration to initiate human clinical trials for their lead pyrimidinedione HIV inhibitor IQP-0410. ImQuest anticipates initiating their Phase 1 studies in the first quarter of 2009. IQP-0410 is a novel small molecule inhibitor of HIV which primarily acts as a nonnucleoside reverse transcriptase inhibitor (NNRTI). The compound possesses a second mechanism of action which prevents the entry of HIV into target cells and significantly raises the potential genetic barrier to resistance with IQP-0410 therapy. Preclinical pharmacokinetic and toxicology studies have demonstrated the potential for once per day dosing and a high safety margin for the compound. IQP-0410 has been found to inhibit HIV replication at sub-nanomolar concentration levels and to have highly significant activity against all clinical virus strains evaluated as well as against multi-drug resistant virus strains obtained from patients failing long courses of therapy with currently approved RT and protease inhibitors. The compound is well suited for use as a component of primary HAART regimens as well as a salvage therapy option. Preclinical studies have also demonstrated the ability of the compound to be used in combination with all other approved HIV drugs.

"The submission of this IND represents a critical milestone in the therapeutic development of the pyrimidinedione class of molecules as potential new HIV drugs and an important success in the strategic drug development initiatives between ImQuest and Samjin Pharmaceutical Co. Ltd of Seoul, KOREA," said Dr. Robert W. Buckheit, Jr., Executive Vice President and Chief Scientific Officer of ImQuest Life Sciences. "We believe that IQP-0410 will be a new and novel addition to the armamentarium of HIV drugs available and provide HIV-infected individuals with a safe and effective alter
'/>"/>

SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
2. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
3. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
4. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
7. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
8. U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
9. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
10. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
11. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., , NATICK, Mass. and LONDON, Nov. 20 /P...ion (NYSE: BSX ) today announced that it has rec... Administration (FDA) and CE Mark approval to mark...nt for the treatment of malignant esophageal stric...with resectable or non-resectable esophageal cance...
(Date:11/20/2009)..., , HOUSTON, Nov. 20 /PRNewswire-FirstC...nounced that Dan Moore, President and Chief Execut...cer, will present at the 21st Annual Piper Jaffray...December 2, 2009 at 12:00 PM EST. The conference ...al slides will be presented. Piper Jaffray will h...
(Date:11/20/2009)..., , FRANKLIN LAKES, N.J., Nov. 20 /PRNewsw...y) (NYSE: BDX ) today announced the completion o... Michigan-based company that develops and manufact...atforms. ,, In May 2009, BD and HandyLab announ...ommercialize molecular assays on the HandyLab Jagu...
Breaking Medicine Technology:Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Drug Might Restore Sense of Smell 51357 1Drug Might Restore Sense of Smell 51357 2Drug Might Restore Sense of Smell 51357 3Texas Humane Legislation Network Calls for Puppy Mill Crackdown 51352 1Texas Humane Legislation Network Calls for Puppy Mill Crackdown 51352 2New Poll Shows Americans Continuing to Move Toward Pro Life Position on Abortion 51348 1New Poll Shows Americans Continuing to Move Toward Pro Life Position on Abortion 51348 2
...7 The Department of,Justice announced today that ...e on Cancer (CRC) to develop and publicize model c...new cancer treatments. The Department said,the lan...be used to help,increase efficiency in contract ne...ing the time needed to begin clinical trials., Th...
...pt. 17 Sanofi pasteur, the,vaccines division of t...s,sponsoring a Phase II clinical study exploring a... advanced-stage melanoma -- an often fatal form of...ons. Patients are being,enrolled in the United Sta...stigate the safety and efficacy of a therapeutic c...
Other Medicine Technology:Justice Department Will Not Oppose CEO Roundtable on Cancer's Proposal 2Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 2Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 4Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 5
(Date:11/20/2009)...swire-USNewswire/ -- The United States Conference ...tial changes its health reform bill in order to ke...nscience protection on abortion, protect access to...visions for adequate affordability. ,, The bish...s disappointment" that creates new and unacceptabl...
(Date:11/20/2009)...wswire-FirstCall/ -- Rates of infection by the 200...ober, but the pandemic flu virus continues to be a...cluding the elderly, according to a new report by ... world,s leading provider of diagnostic testing, i... Quest Diagnostics Health Trends(TM) Report "Testi...
(Date:11/20/2009)...20 Cardio Vascular,Medic....COM , a leading,developer of advanced cardiovascu...ompany,s Board of Directors has decided to initiat...r East for its proprietary next-generation,"steera...A) procedures. , Cardio Vascular Medical ...
(Date:11/20/2009)...ire-FirstCall/ -- SIRIUS XM Radio (Nasdaq: SIRI... Radio Reports: What Every Women Needs to Know Ab...eran journalist Perri Peltz. ,, (Logo: http:/... ) ,, Doctor Radio Reports: What Every Woman...er 21 live at 10:00 am ET on Doctor Radio , SIRIU...
(Date:11/20/2009)... with chronic kidney disease often fail to detect ...increasing a child,s risk for serious heart proble...ren,s Center and other institutions. A report of t...can Society of Nephrology. , Researchers compa...gular doctor visits to readings obtained via a spe...
Breaking Medicine News(10 mins):Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:High blood pressure easy to miss in children with kidney disease 2
...mber 11, 2007 Takeda Pharmaceuticals North Americ...one HCl) data conducted by A. Michael Lincoff, M.D...ed in the Journal of the American Medical Associat...tients with diabetes versus control therapy. , ...
...ostate biopsies resulted in a cancer diagnosis amo...e first biopsy did not find cancer often had multi...ance of a cancer diagnosis. , While PSA (prostat...Nonetheless, it remains unclear whether or not PSA...
...n now have another good reason to consider taking ...s an enlarged prostate and reduces the risk of get...om the Southwest Oncology Group strongly suggests ...ncers early, when they are most easily treatable. ...
...arker, not a cause, of renal trouble, study sugges...-- Lowering blood levels of an inflammation-linke...th serious kidney disease live any longer, new res...e who took extra folic acid, vitamin B6 and vitami...
...11 Dr. Walter,Cottrell, Pennsylvania Game Commiss...e test result from an adult female deer has confir...een found in Beaver County., "This outbreak of EH...dition, the fact that we are finding EHD earlier,t...
...s Conclude Sweetener Is Safe Across Population ...Sept. 11 A report published in the,September issu...sue 8, pp.,629-727) systematically evaluates virtu...of eight recognized scientists,from research insti...
Other Medicine News:Health News:Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association 2Health News:Other highlights in the September 11 JNCI 2Health News:Other highlights in the September 11 JNCI 3Health News:Generic prostate drug helps find high-risk cancers early 2Health News:Generic prostate drug helps find high-risk cancers early 3Health News:Lowering Blood Protein Won't Help Kidney Patients 2Health News:Lowering Blood Protein Won't Help Kidney Patients 3Health News:PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County 2Health News:PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County 3Health News:PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County 4Health News:New Expert Report Dispels Common Myths About Aspartame 2Health News:New Expert Report Dispels Common Myths About Aspartame 3
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: